MyFinsight
Home
Blog
About
Oral Solid
$175,172K
(-1.73%↓ Y/Y)
Other Dosage Forms
$81,594K
(19.67%↑ Y/Y)
Transdermal
$67,038K
(64.67%↑ Y/Y)
Ephinephrine Auto Injector
$62,214K
(-6.58%↓ Y/Y)
Injectable
$56,783K
(63.89%↑ Y/Y)
Biosimilar
$29,128K
(15.37%↑ Y/Y)
Oral Liquid
$10,371K
(-41.99%↓ Y/Y)
Central Nervous System
$95,344K
(14.29%↑ Y/Y)
Hormonal Allergy
$42,099K
(18.86%↑ Y/Y)
Other Therapeutic
Classes
$11,852K
(36.23%↑ Y/Y)
Subtotal Dosage Forms
$482,300K
(11.77%↑ Y/Y)
International
$7,613K
(300.47%↑ Y/Y)
Distribution Service
$86,930K
(-12.78%↓ Y/Y)
Government Label
$50,207K
(10.54%↑ Y/Y)
Institutional
$12,112K
(19.54%↑ Y/Y)
Product And Service
Other
$7,740K
(-1.11%↓ Y/Y)
Revenue From Contract
With Customer...
$149,295K
Affordable Medicines
Segment
$489,913K
(24668.10%↑ Y/Y)
Av KARESegment
$156,989K
(-3.71%↓ Y/Y)
Specialty Segment
$149,295K
(16.60%↑ Y/Y)
Net revenue
$796,197K
(9.89%↑ Y/Y)
Gross profit
$334,508K
(16.86%↑ Y/Y)
Other operating
income
$1,298K
Cost of goods sold
$461,689K
(5.35%↑ Y/Y)
Operating income
$129,769K
(16.52%↑ Y/Y)
Selling, general and
administrative
$148,722K
(19.68%↑ Y/Y)
Research and development
$39,017K
(-18.65%↓ Y/Y)
Charges (credit)
related to legal...
-$8,057K
(-2165.90%↓ Y/Y)
Acquisition costs
$7,600K
Intellectual property legal
development expenses
$2,087K
(3.47%↑ Y/Y)
Restructuring and other
charges
$554K
(-45.90%↓ Y/Y)
Income before income
taxes
$70,990K
(37.28%↑ Y/Y)
Total other expense,
net
-$58,779K
(1.48%↑ Y/Y)
Other income, net
$653K
(-59.29%↓ Y/Y)
Net income
$69,614K
(95.49%↑ Y/Y)
Provision for income taxes
$1,376K
(-91.45%↓ Y/Y)
Interest expense, net
-$55,043K
(15.45%↑ Y/Y)
Increase in tax
receivable agreement...
-$2,439K
(44.82%↑ Y/Y)
Foreign exchange (gain)
loss, net
-$1,950K
(-123.62%↓ Y/Y)
Back
Back
Income Statement
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)
source: myfinsight.com